HDAC9 and breast carcinoma: In addition, by increasing secretory pathway calcium ATPase 2 (SPCA2) expression, HDAC inhibitors encourage the transition from mesenchymal to epithelial in triple negative breast cancer cell lines, indicating that aberrant epigenetic regulation of SPCA2 is linked to poor prognosis and breast cancer metastasis [28].